Top Markets
Coin of the day
Acorda Therapeutics, Inc. Acorda Therapeutics, Inc.

Acorda Therapeutics, Inc.

ACOR
Kedudukan dalam Saham #39255
Acorda Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering,... Acorda Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing treatments for conditions affecting the nervous system, primarily within the United States. Its current product offerings include Ampyra (dalfampridine), an oral medication prescribed to enhance walking ability in individuals with multiple sclerosis (MS). The company also distributes Inbrija in Europe, which is used to manage "OFF" periods experienced by Parkinson's disease patients. Globally, Ampyra is recognized and sold as Fampyra across Europe, Asia, and the Americas. Beyond its existing products, Acorda is actively advancing several experimental therapies: ARCUS for the management of acute migraine attacks, rHIgM22 which has successfully completed Phase I clinical trials for MS, and Cimaglermin alfa, currently being investigated for patients with heart failure. The company holds a licensing and collaborative agreement with Biogen Inc. for the ongoing development and market distribution of Ampyra. Acorda Therapeutics, Inc. was founded in 1995 and operates from its headquarters in Ardsley, New York.
Harga Saham
$0.879
Disegerakkan terakhir: 2024-05-07
Modal Pasaran
$582.38K
Perubahan (1 hari)
9.88%
Perubahan (1 tahun)
0.00%
Negara
US
Perdagangan Acorda Therapeutics, Inc. (ACOR)

Kategori

Sejarah hasil dividen untuk Acorda Therapeutics, Inc. (ACOR)
Hasil dividen (TTM) bagi Acorda Therapeutics, Inc. (simbol saham: ACOR) pada 2026 adalah: 0
Purata hasil dividen 5 tahun terakhir: 0.00%
Sejarah hasil dividen untuk Acorda Therapeutics, Inc. (ACOR) dari 2026 hingga 2026
Hasil dividen pada akhir setiap tahun (TTM)
Tahun Hasil Dividen Ubah
Tidak cukup data untuk tarikh yang disediakan.
Hasil dividen (TTM) untuk syarikat serupa atau pesaing